Table 4 Multivariable Cox-proportional hazards analysis of predictors of 5- year disease-free survival
HR (95% CI) | p-value | |
|---|---|---|
Stage | ||
Regional | 3.1 (2.7–3.7) | < 0.001 |
Metastatic | 8.2 (6.7–10.0) | < 0.001 |
Tumor size | ||
≥ 2 to < 3 cm | 1.1 (0.9–1.3) | 0.351 |
≥ 3 to < 5 cm | 1.1 (0.9–1.3) | 0.281 |
≥ 5 cm | 1.9 (1.6–2.4) | < 0.001 |
Unknown | 1.2 (0.9–1.5) | 0.236 |
Radioactive iodine | ||
Yes | 0.7 (0.6–0.8) | < 0.001 |
Hospital volume (vs. average < 15 thyroidectomies yearly) | ||
15 to < 30 | 1.0 (0.9–1.2) | 0.574 |
30–55 | 0.7 (0.6–0.9) | 0.001 |
55+ | 1.0 (0.8–1.2) | 0.618 |
Surgery performed (vs. thyroid lobectomy) | ||
Completion thyroidectomy | 0.6 (0.4–1.1) | 0.096 |
Total thyroidectomy | 1.3 (1.0–1.6) | 0.014 |
Total thyroidectomy with cervical lymphadenectomy | 1.8 (1.4–2.2) | < 0.001 |
Race (vs. non-hispanic white) | ||
Non-Hispanic Black | 1.0 (0.7–1.5) | 0.951 |
Hispanic | 1.5 (1.3–1.7) | < 0.001 |
Asian/Pacific Islander | 1.2 (1.0–1.4) | 0.060 |
Other race/Unknown | 1.1 (0.8–1.6) | 0.407 |
Age | ||
45–59 | 1.3 (1.1–1.5) | < 0.001 |
≥ 60 | 2.3 (1.9–2.8) | < 0.001 |
Gender | ||
Female | 0.9 (0.7–1.0) | 0.039 |
Comorbidities (vs. none) | ||
1 | 1.3 (1.1–1.6) | < 0.001 |
2 or more | 1.4 (1.0–2.0) | 0.031 |
Insurance (vs. private/hmo) | ||
Medicare | 0.9 (0.8–1.1) | 0.601 |
Medicaid/Indigent | 1.1 (0.9–1.3) | 0.568 |
County/Tricare/Military/VA | 1.5 (0.8–2.8) | 0.199 |
Not Insured/Other/Unknown | 4.5 (3.2–6.2) | < 0.001 |